DTR: Year-End 2021 Portfolio Review & 2022 Outlook (Part 1)
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
Here are the key takeaways and fundamentals from Atomera’s (ATOM) quarterly report that suggest a surge to $100+ per share is on the horizon
Every time Cue Biopharma (CUE) attends a conference, management shares new platform-validating data. Here’s what to expect today…
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
Here are three key takeaways from the FDA’s response to Provention Bio (PRVB)’s BLA application for teplizumab…
Here’s what to expect this week from Provention Bio (PRVB) as the FDA’s original PDUFA date hits on Friday…
A comprehensive review of all recommendations, including the latest developments, upcoming catalysts, risks, as well as price and profit targets.
Cue Biopharma (CUE) released a major, platform validating data this morning. Here are the 5 key takeaways…
Ignore the short-term price action in Atomera (ATOM) and focus on the steadily improving business fundamentals…
The latest data out of Immunome underscores the superiority of its approach and demonstrates why the stock could be the next high-flying Novavax (NVAX)